Skip to main content

96 percent of the world’s genetic data is from white people — here’s how we change that

genomics developing world 52414187  group of diverse hands together joining concept
Image used with permission by copyright holder
Genuinely paradigm-shifting achievements don’t come along every day, year or, heck — even every decade.

The Human Genome Project, however, was one notable exception to that rule. Decoding the genome in the early-2000s was a game changer. It wasn’t as immediately wondrous as the Moon landing, or as immediately fearsome as the atomic bomb, but it hinted at the promise of an amazing future: one in which a person’s genetic predisposition to disease could be unravelled early enough for them to act. Genome scanning would move us from a world of reactive medicine to one of proactive medicine; forever banishing the one-size-fits-all approach.

Recommended Videos

“60 percent of the world’s population comprises less than one percent of the world’s genomic data”

Jump forward around a decade-and-a-half and that dream is still becoming a reality, but it’s a slow process.

“The technology is ready,” Sumit Jamuar told Digital Trends. “It’s better, faster, cheaper, whether you look at frameworks or sequencing. But the data is missing.”

Jamuar is the co-founder and CEO of a genetics company called Global Gene Corp., whose R&D center is located in Cambridge, England. The startup’s mission? To democratize genomics research by making it available to people throughout the world.

“One statistic which staggered me when we first looked at the data is that 60 percent of the world’s population comprises less than one percent of the world’s genomic data,” Jamuar said. “There are more than 3 billion people who do not contribute sufficient genomic data. To deliver any precision medicine programs in these countries means that pharmaceutical and medical companies need to have that data. This isn’t just looking at the top 1 million or 10 million people; if we have done our job correctly we will have a real impact on a significant population set of 3 billion people of different ethnicities all around the world. To me, that is the meaning of democratizing a technology.”

Image used with permission by copyright holder

The caucasian-centric genomics data that presently makes up the bulk of available data isn’t a conspiracy. The funding for the Human Genome Project came from the United States and United Kingdom, both of which have predominantly white populations. Developing nations like India and Africa, meanwhile, have lagged behind in this research — although interest is growing.

“Many of these other governments already have their budgets stretched by fighting communicable diseases and other elements which are a priority in the immediate term,” he continued. “The good news is that as these communicable diseases are eradicated — such as India being made polio free — you can focus on the bigger threats. These are the non communicable diseases, like heart disease, cancer and the like. Those inherently have genetic codes.”

“There are more than 3 billion people who do not contribute sufficient genomic data”

Diversity in genomic data is hugely important. For instance, Indians frequently suffer from diabetes in greater proportional numbers than Westerners. The same is true with colon cancer among young people, which is at higher levels in India than in America, although just 0.2 percent of available genomic data comes from India — which holds 20 percent of the world’s population. Indian populations who suffer from colon cancer additionally show different genetic mutations from patients in Western countries. Being able to analyze genomics data for populations outside of predominantly caucasian ones means that a great degree of understanding of these issues can be gathered. It also means personalized medical treatments can be made more effective in the process.

Global Gene Corp. is working with hospitals, research organizations and individuals to gather its genomics information. It is also striving to bring the price point down to levels that are achievable in developing nations with much lower median earnings. The goal is then to use cutting-edge machine learning tools to help make sense of the data, and to draw useful correlations.

Image used with permission by copyright holder

This is where Jamuar said the value will come. He draws a parallel between personal computing in the 1980s, when it was just starting to develop the “killer apps” which made it useful to everyday consumers, and genomics-based healthcare in 2017.

Far from just a “nice to have” luxury, Jamuar pointed out that investment in this area can help cut down on wasting expensive drugs, which may prove ineffective fighting certain diseases. “The world is spending about $200 billion on cancer drugs, where you can estimate ¾ are not effective,” he said. “The same is true with many asthma drugs.”

It’s all part of a broader shift he sees taking place in which the world moves toward personalized healthcare.

“Right now, we have a symptom and we go to the doctor with it,” he said. “We then get an intervention, which could take the form of a drug which may or may not work. Twenty years from now I think that people will look back and say, ‘that’s so medieval. I can’t believe you ever used that kind of hit-and-miss experimentation.’ What will instead happen is that we’ll have data for every individual and that will give us the ability to predict the best way to avoid disease on a personal basis. It also opens up the possibility of using gene editing, where you can fix certain mutations in a person’s genetic sequence. It will be possible to do tailored treatment for every individual.”

Certainly it’s an ambitious mission, and one that will require considerable private and public funding, but it’s a crucial next step to take as genomics research continues.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Range Rover’s first electric SUV has 48,000 pre-orders
Land Rover Range Rover Velar SVAutobiography Dynamic Edition

Range Rover, the brand made famous for its British-styled, luxury, all-terrain SUVs, is keen to show it means business about going electric.

And, according to the most recent investor presentation by parent company JLR, that’s all because Range Rover fans are showing the way. Not only was demand for Range Rover’s hybrid vehicles up 29% in the last six months, but customers are buying hybrids “as a stepping stone towards battery electric vehicles,” the company says.

Read more
BYD’s cheap EVs might remain out of Canada too
BYD Han

With Chinese-made electric vehicles facing stiff tariffs in both Europe and America, a stirring question for EV drivers has started to arise: Can the race to make EVs more affordable continue if the world leader is kept out of the race?

China’s BYD, recognized as a global leader in terms of affordability, had to backtrack on plans to reach the U.S. market after the Biden administration in May imposed 100% tariffs on EVs made in China.

Read more
Tesla posts exaggerate self-driving capacity, safety regulators say
Beta of Tesla's FSD in a car.

The National Highway Traffic Safety Administration (NHTSA) is concerned that Tesla’s use of social media and its website makes false promises about the automaker’s full-self driving (FSD) software.
The warning dates back from May, but was made public in an email to Tesla released on November 8.
The NHTSA opened an investigation in October into 2.4 million Tesla vehicles equipped with the FSD software, following three reported collisions and a fatal crash. The investigation centers on FSD’s ability to perform in “relatively common” reduced visibility conditions, such as sun glare, fog, and airborne dust.
In these instances, it appears that “the driver may not be aware that he or she is responsible” to make appropriate operational selections, or “fully understand” the nuances of the system, NHTSA said.
Meanwhile, “Tesla’s X (Twitter) account has reposted or endorsed postings that exhibit disengaged driver behavior,” Gregory Magno, the NHTSA’s vehicle defects chief investigator, wrote to Tesla in an email.
The postings, which included reposted YouTube videos, may encourage viewers to see FSD-supervised as a “Robotaxi” instead of a partially automated, driver-assist system that requires “persistent attention and intermittent intervention by the driver,” Magno said.
In one of a number of Tesla posts on X, the social media platform owned by Tesla CEO Elon Musk, a driver was seen using FSD to reach a hospital while undergoing a heart attack. In another post, a driver said he had used FSD for a 50-minute ride home. Meanwhile, third-party comments on the posts promoted the advantages of using FSD while under the influence of alcohol or when tired, NHTSA said.
Tesla’s official website also promotes conflicting messaging on the capabilities of the FSD software, the regulator said.
NHTSA has requested that Tesla revisit its communications to ensure its messaging remains consistent with FSD’s approved instructions, namely that the software provides only a driver assist/support system requiring drivers to remain vigilant and maintain constant readiness to intervene in driving.
Tesla last month unveiled the Cybercab, an autonomous-driving EV with no steering wheel or pedals. The vehicle has been promoted as a robotaxi, a self-driving vehicle operated as part of a ride-paying service, such as the one already offered by Alphabet-owned Waymo.
But Tesla’s self-driving technology has remained under the scrutiny of regulators. FSD relies on multiple onboard cameras to feed machine-learning models that, in turn, help the car make decisions based on what it sees.
Meanwhile, Waymo’s technology relies on premapped roads, sensors, cameras, radar, and lidar (a laser-light radar), which might be very costly, but has met the approval of safety regulators.

Read more